Laos becomes the 20th country to authorize the one-shot Sputnik Light vaccine
MOSCOW, Nov. 24, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today announced the Russian single-component Sputnik Light vaccine against coronavirus has been approved in Lao People's Democratic Republic. Thus Laos has become the 20th country to register Sputnik Light. Sputnik Light vaccine is based on human adenovirus serotype 26, which is the first component...
Baird Medical to Participate in the American Thyroid Association (ATA) Annual Meeting
NEW YORK, Oct. 14, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading developer and provider of microwave ablation ("MWA") medical devices in China, which recently expanded into the U.S. market following its U.S. FDA 510(k) clearances, today announced its participation in the upcoming American Thyroid Association (ATA) Annual Meeting....
Nippon Express Europe Exhibits at LogiPharma 2023 for First Time
TOKYO, June 15, 2023 /PRNewswire/ -- Nippon Express Europe GmbH, a group company of NIPPON EXPRESS HOLDINGS, INC., exhibited for the first time at "LogiPharma 2023" held in Lyon, France, from Tuesday, April 25, to Thursday, April 27. Logo: https://kyodonewsprwire.jp/img/202306136298-O1-VPF88v28 Photo: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202306136298/_prw_PI2fl_NJKJYRjE.jpg?_ga=2.3372912.1997240702.1686531031-1438572707.1685531252 LogiPharma 2023 is one of the world's largest international pharmaceutical trade shows, focusing on issues, trends...
MediLink Therapeutics: Focuses on ADC research and development to promote new prospects for cancer treatment
----- YL201 Phase I/II Investigators Meeting was successfully held in Guangzhou, China GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ -- On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The chair of this meeting was...
Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for...
Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts
Twenty studies validate AI performance across diverse populations and clinical settings, including award-winning research in emergency radiology SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced its participation in the Radiological Society of North America (RSNA) 2024 Annual...
FII 5th Anniversary Brings Together 250+ Leaders to Invest in Humanity
· The 5th Anniversary of the Future Investment Initiative will be held October 26 – 28 in the Saudi capital Riyadh under the theme "Invest in Humanity". · More than 250 speakers will attend, including heads of state, global executives, policymakers, investors, and innovators. RIYADH, Saudi Arabia, Oct. 14, 2021 /PRNewswire/ -- The 5th Anniversary of the Future Investment Initiative (FII), set to take place October 26 – 28 in...
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
Poster presentation features the interim data from an ongoing Phase 1b clinical trial of TU2218 plus Keytruda combination therapy in patients with advanced solid tumors A 40% overall response rate (ORR) and 100% disease control rate (DCR) were achieved in high-dose cohort (195 mg/day) TU2218 was well-tolerated as a monotherapy and combination therapy...
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an...
AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program
TOKYO, June 30, 2025 /PRNewswire/ -- AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapies for hematologic cancers and autoimmune diseases, today announced it has been awarded a grant of up to $40 million from the Japan Agency for Medical Research...
